PharmaDrug Inc. announced that current board member Dr. David Kideckel has been appointed Chairman of the Board of PharmaDrug replacing Robert Steen who will remain as CEO of the Company. As Founder of the Kideckel Advisory Group Inc., David provides fractional CFO and CBO services to both public and private corporations. David combines nearly 20 years of industry, advisory, and capital markets experience, most recently serving as Managing Director, Head of Life Sciences &Senior Institutional Equity Research Analyst at ATB Capital Markets.

David's industry experience spans several senior healthcare &biotechnology executive roles including at Johnson &Johnson Inc. and Alexion Pharmaceuticals (acquired by AstraZeneca PLC). David holds a Doctorate in Neuroscience &Statistics from the University of Toronto's Institute of Medical Science and an MBA from the University of Toronto's Rotman School of Management.